Search

Your search keyword '"Diamant, Zuzana"' showing total 36 results

Search Constraints

Start Over You searched for: Author "Diamant, Zuzana" Remove constraint Author: "Diamant, Zuzana" Publisher wiley-blackwell Remove constraint Publisher: wiley-blackwell
36 results on '"Diamant, Zuzana"'

Search Results

1. EUFOREA/EPOS2020 statement on the clinical considerations for chronic rhinosinusitis with nasal polyps care.

2. Sustained efficacy of mepolizumab in patients with severe chronic rhinosinusitis with nasal polyps: SYNAPSE 24‐week treatment‐free follow‐up.

3. Eosinophils—from cradle to grave: An EAACI task force paper on new molecular insights and clinical functions of eosinophils and the clinical effects of targeted eosinophil depletion.

4. Standardization of clinical outcomes used in allergen immunotherapy in allergic asthma: An EAACI position paper.

5. Efficacy of FP‐025: A novel matrix metalloproteinase‐12 (MMP‐12) inhibitor in murine allergic asthma.

6. Neutrophil phenotypes in bronchial airways differentiate single from dual responding allergic asthmatics.

7. Physical exercise, immune response, and susceptibility to infections—current knowledge and growing research areas.

8. Effects of non‐steroidal anti‐inflammatory drugs and other eicosanoid pathway modifiers on antiviral and allergic responses: EAACI task force on eicosanoids consensus report in times of COVID‐19.

9. Real-life assessment of chronic rhinosinusitis patients using mobile technology: The mySinusitisCoach project by EUFOREA.

10. Comparing biologicals and small molecule drug therapies for chronic respiratory diseases : An EAACI Taskforce on Immunopharmacology position paper

11. Comparing biologicals and small molecule drug therapies for chronic respiratory diseases: An EAACI Taskforce on Immunopharmacology position paper

12. Cysteinyl–leukotriene and prostaglandin pathways in bronchial versus alveolar lavage in allergic asthmatics.

13. Vaccines and allergic reactions: The past, the current COVID‐19 pandemic, and future perspectives.

14. COVID‐19 pandemic: Practical considerations on the organization of an allergy clinic—An EAACI/ARIA Position Paper.

15. The ICQ asthma algorithm: Inhaled corticosteroid Containing resCUE (ICQ) treatment for present and future asthma management.

16. Immune modulation via T regulatory cell enhancement: Disease‐modifying therapies for autoimmunity and their potential for chronic allergic and inflammatory diseases—An EAACI position paper of the Task Force on Immunopharmacology (TIPCO).

17. Current perspective on eicosanoids in asthma and allergic diseases: EAACI Task Force consensus report, part I.

18. Biomarkers for diagnosis and prediction of therapy responses in allergic diseases and asthma.

19. A compendium answering 150 questions on COVID‐19 and SARS‐CoV‐2.

20. The need for clean air: The way air pollution and climate change affect allergic rhinitis and asthma.

21. COVID‐19, chronic inflammatory respiratory diseases and eosinophils—Observations from reported clinical case series.

22. Blood eosinophils: In quest of a Holy Grail for personalized asthma treatment with biologicals.

23. Future research trends in understanding the mechanisms underlying allergic diseases for improved patient care.

24. EUFOREA consensus on biologics for CRSwNP with or without asthma.

25. The potential role of CD16highCD62Ldim neutrophils in the allergic asthma.

26. Prioritizing research challenges and funding for allergy and asthma and the need for translational research—The European Strategic Forum on Allergic Diseases.

27. Toward clinically applicable biomarkers for asthma: An EAACI position paper.

28. Much ado about Biologicals: Highlights of the Master Class on Biologicals, Prague, 2018.

29. Comparing biologicals and small molecule drug therapies for chronic respiratory diseases: An EAACI Taskforce on Immunopharmacology position paper.

30. Point‐of‐care biomarkers in asthma management: Time to move forward.

32. Single- and multiple-dose tolerability and pharmacokinetics of the CRTH2 antagonist setipiprant in healthy male subjects.

33. Clinical aspects of using exhaled NO in asthma diagnosis and management.

34. Real-life assessment of chronic rhinosinusitis patients using mobile technology: The mySinusitisCoach project by EUFOREA.

35. Severe asthma: Entering an era of new concepts and emerging therapies: Highlights of the 4th international severe asthma forum, Madrid, 2018.

36. The potential role of CD16 high CD62L dim neutrophils in the allergic asthma.

Catalog

Books, media, physical & digital resources